Tolebrutinib associated with long-term safety, efficacy in relapsing-remitting MS
BOSTON — Treatment with tolebrutinib 60 mg per day was safe and associated with low annualized relapse rate and stable disability through 120 weeks, according to research presented at the American Academy of Neurology annual meeting.“In the MS field, we need treatments that can better target both peripheral and centrally mediated inflammation, and I think there is a lot of hope for
Source: healio.com